Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structurally Based Design of Glucagon Mutants That Inhibit Fibril Formation.

Biochemistry - 29 Jun 2021

Gelenter Martin D, Dregni Aurelio J, Duan Pu, Hong Mei

Abstract excerpt

The peptide hormone glucagon is prescribed as a pharmaceutical compound to treat diabetic hypoglycemia. However, at the acidic pH where it is highly soluble, glucagon rapidly aggregates into inactive and cytotoxic amyloid fibrils. The recently determined high-resolution structure of these fibrils revealed various stabilizing molecular interactions. On the basis of this structure, we have now designed four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidogenic Proteins
Share to Drug Design
Share to Glucagon

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Nuclear Magnetic Resonance, Biomolecular

Share to Protein Conformation, alpha-Helical

Share to Sodium Chloride

Share to Solubility

Source

Open in PubMed Open full text

Identifiers

PMID: 34124902
DOI: 10.1021/acs.biochem.1c00214
PMCID: PMC8254510

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structurally Based Design of Glucagon Mutants That Inhibit Fibril Formation.PMID 34124902Read ↗

N- and C-terminal hydrophobic patches are involved in fibrillation of glucagon.Semantic proximity Read ↗

Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones.Semantic proximity Read ↗

Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility.Semantic proximity Read ↗

Structural effects driven by rare point mutations in amylin hormone, the type II diabetes-associated peptideSemantic proximity Read ↗

Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.Semantic proximity Read ↗

Probing the mechanism of insulin fibril formation with insulin mutants.Semantic proximity Read ↗

Structural basis for the identification of short novel peptides as potential GLP1R agonists using in silico approachesSemantic proximity Read ↗

Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation.Semantic proximity Read ↗

A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.Semantic proximity Read ↗

Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action.Semantic proximity Read ↗

Mutational analysis of preamyloid intermediates: the role of his-tyr interactions in islet amyloid formation.Semantic proximity Read ↗

Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.